Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Gynecologic and Breast Cancer Survivors

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of Washington
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01641068
First received: July 12, 2012
Last updated: February 14, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to examine thinking abilities, mood, and quality of life in cancer survivors before and after an 8-week group-based memory and thinking skills workshop. Research participants will include people treated for cancer in the past. Researchers would like to know if there is a relationship between baseline performance on timed attention and memory tasks before receiving memory and thinking skills workshop, and performance on such tasks after the workshop.


Condition Intervention
Breast Cancer
Cancer Survivor
Cognitive/Functional Effects
Female Reproductive Cancer
Other: cognitive intervention
Other: questionnaire administration
Procedure: quality-of-life assessment
Procedure: blood-oxygen-level-dependent functional magnetic resonance imaging
Other: memory intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study.

Resource links provided by NLM:


Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Changes in cognitive performance pre and post participation in a cognitive rehabilitation intervention [ Time Frame: Baseline to 7 weeks ] [ Designated as safety issue: No ]
    The behavioral data (tests and questionnaires) will be entered into SPSS statistical software and analyzed. A mixed model (group by time) multivariate analysis of variance (MANOVA) will be used to determine if an interaction occurs between the treatment group and control (CL) over time, which will be further confirmed with post-hoc analyses.

  • Changes in QOL pre and post participation in a cognitive rehabilitation intervention [ Time Frame: Baseline to 7 weeks ] [ Designated as safety issue: No ]
    The behavioral data (tests and questionnaires) will be entered into SPSS statistical software and analyzed. A mixed model (group by time) MANOVA will be used to determine if an interaction occurs between the treatment group and CL over time, which will be further confirmed with post-hoc analyses.

  • Changes in neural function measured by fMRI BOLD signal and corresponding behavioral responses while performing cognitive tasks [ Time Frame: Baseline to 7 weeks ] [ Designated as safety issue: No ]
    Software from the fMRI for the brain Software Library will be used to analyze fMRI data and a paired T-test will be used to compare resting state images with paired associate recall images. Prior to automated procedures each functional series will be manually reviewed and aberrant volumes or extreme motion artifacts will be removed. Both a whole brain and region of interest analysis will be conducted for cognitive task scans.


Estimated Enrollment: 15
Study Start Date: September 2012
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (memory and thinking skills workshop)
Patients participate in a memory and thinking skills workshop once weekly for 8 weeks. Patients complete cognitive tests and questionnaires at baseline and 7 weeks.
Other: cognitive intervention
Participate in memory and thinking skills workshop
Other: questionnaire administration
Ancillary studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Procedure: blood-oxygen-level-dependent functional magnetic resonance imaging
Undergo BOLD-fMRI
Other Name: BOLD fMRI
Other: memory intervention
Participate in memory and thinking skills workshop
Active Comparator: Arm II (control)
Patients complete cognitive tests and questionnaires at baseline and 7 weeks. Patients are then scheduled to participate in a later memory and thinking skills workshop.
Other: questionnaire administration
Ancillary studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Procedure: blood-oxygen-level-dependent functional magnetic resonance imaging
Undergo BOLD-fMRI
Other Name: BOLD fMRI

Detailed Description:

PRIMARY OBJECTIVES:

I. To objectively assess changes in cognitive performance and quality of life (QOL) pre and post participation in a cognitive rehabilitation intervention in gynecologic and breast cancer survivors who have undergone chemotherapy.

II. To measure changes in neural function as measured by functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signal and corresponding behavioral responses while performing cognitive tasks.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients participate in a memory and thinking skills workshop once weekly for 8 weeks. Patients complete cognitive tests and questionnaires at baseline and 7 weeks.

ARM II: Patients complete cognitive tests and questionnaires at baseline and 7 weeks. Patients are then scheduled to participate in a later memory and thinking skills workshop.

  Eligibility

Ages Eligible for Study:   21 Years to 90 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjective concern about declines in cognitive functioning related to a diagnosis of cancer and/or cancer related treatment
  • Prior treatment of gynecologic or breast cancer with chemotherapy
  • Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the past
  • Able to comprehend and speak English
  • For the subset of participants who will undergo magnetic resonance imaging (MRI), ability to withstand lying down in small area (MRI scanner) for 50 minutes
  • Completion of successful fMRI safety screening
  • Able to give informed consent
  • Able to undergo informed consent procedures and 3 hours of testing, plus 8 1-hour cognitive rehabilitation sessions with breaks

Exclusion Criteria:

  • Ongoing treatment for ovarian or other cancer (e.g., chemotherapy, radiation, surgery, etc.)
  • Cancer onset before the age of 21
  • Unstable medical problems (such as unstable heart disease, unstable hypertension, diabetes in poor control, respiratory disease complicated by hypoxia or hypercapnia, infectious illnesses, unstable thyroid dysfunction, currently hospitalized)
  • History of, or current symptoms of, serious psychiatric disorder requiring antipsychotic medications or hospitalization; mild depression or stable anti-depressants, and anti-seizure medications are acceptable; anti-anxiety medications may be acceptable
  • Current alcohol over-use as defined by currently consuming 4 drinks or more per day or binge drinking (6 or more drinks in one night) within the past week
  • History of or current neurological illness that significantly impacts cognition (e.g. stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, head injury, epilepsy, etc)
  • History of brain injury that significantly impacted cognition; as indicated responses on the Ohio State University Traumatic Brain Injury Identification Method (OSU TBI-ID) greater or equal to any of the following: 30 minutes or more of loss of consciousness (LOC), two or more mild cases within two weeks of each other, or any injury with loss of consciousness before the age of 15
  • History of central nervous system (CNS) tumor
  • A score of 25 or more on the Patient Health Questionnaire (PHQ-9) on the first visit
  • A score of 26 or below on the Mini Mental Status Exam (MMSE) triggers a review by an investigational team before enrolling
  • A score above 45 on the Wender Utah Rating Scale for attention deficit disorder (ADD) (WURS)
  • For the subset of participants undergoing neuroimaging:

    • Medical history or devices which make an MRI unsafe or uncomfortable (e.g., magnetic rods or pins, metal plates or screws, pacemaker)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01641068

Locations
United States, Washington
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Recruiting
Seattle, Washington, United States, 98109
Contact: Heidi J. Gray    206-543-3669      
Principal Investigator: Heidi J. Gray         
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Heidi Gray Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
  More Information

No publications provided

Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01641068     History of Changes
Other Study ID Numbers: 7750, NCI-2012-01035, 7750, P30CA015704
Study First Received: July 12, 2012
Last Updated: February 14, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 20, 2014